Cargando…
Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?
Melanomas harboring an activating BRAFV600 mutation account for 50% of all advanced melanomas. The approval of BRAF-targeted therapy revolutionized treatment of these patients with achievement of impressive responses. However, development of resistance to these drugs is a significant problem, and as...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036333/ https://www.ncbi.nlm.nih.gov/pubmed/35478991 http://dx.doi.org/10.1177/17588359221090306 |